Skip to content
drillr.ai
Sign up

DMAAU

Drugs Made In America Acquisition Corp.

NASDAQ · Financial Services · Financial - Conglomerates · US

Also listed · DMAA →DMAAR →
$10.82
+0.28%
Ask drillr
Price chart
Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11Sep 16
Key dataSep 16, 2026
Open
$10.79
From 52W high
−4.42%
Volume
0.00
Market cap
$362.66M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−138.1x
P/E (TTM)
55.1x
RSI (14)
37.4
MomentumView details →
1D Return
+0.28%
YTD Return
+2.66%
SummaryUpdated Jun 1, 2026

Drugs Made In America Acquisition Corp. (NASDAQ:DMAAU) is a special purpose acquisition company (SPAC) founded on May 23, 2024, and headquartered in Fort Lauderdale, Florida. The company went public on January 27, 2025, as a blank check company designed to identify and merge with or acquire businesses in the pharmaceutical and healthcare sectors. As a newly formed entity, DMAAU operates as an investment vehicle seeking to complete a business combination with one or more target companies, with a particular focus on businesses involved in domestic pharmaceutical manufacturing and related healthcare services.

Ask drillr about Drugs Made In America Acquisition Corp. →

Similar companies

Karbon Capital Partners Corp. UnitsKBONUCrane Harbor Acquisition Corp. II UnitsCRANULendingTree, Inc.TREEAMR Resources Acquisition Corp Class A Ordinary SharesAMACAldabra 4 Liquidity Opportunity Vehicle Inc.ALOVBleichroeder Acquisition Corp. IIBBCQ
Latest newsMore news →
Drugs Made In America Acquisition Corp. entered into an Amended and Restated Definitive Merger Agreement with Power Analytics Global Corp, fixing a closing valuation of US$2.85 billion for the merger.6d ago